35 studies found for:    BLyS
Show Display Options
Rank Status Study
1 Completed B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency
Condition: IgA Deficiency
Intervention: Drug: B-Lymphocyte Stimulator (BLyS)
2 Completed BLYS and IFN in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: fluzone;   Biological: pneumovax
3 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
4 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab
5 Not yet recruiting Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
Condition: Systemic Lupus Erythematosus
Intervention: Biological: belimumab
6 Completed
Has Results
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
7 Recruiting Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg;   Other: placebo
8 Terminated Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Condition: Desensitization Before Kidney Transplant
Intervention: Drug: Belimumab
9 Terminated
Has Results
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
Condition: Arthritis, Rheumatoid
Intervention: Drug: ofatumumab
10 No longer available Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
Condition: Rheumatoid Arthritis
Intervention: Drug: belimumab
11 Terminated
Has Results
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
Condition: Rheumatoid Arthritis
Intervention: Drug: belimumab
12 Active, not recruiting A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Condition: Systemic Lupus Erythematosus
Intervention: Biological: Belimumab
13 Completed Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: LimphoStat-B
14 Active, not recruiting A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
15 Completed
Has Results
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
16 Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab 1 mg/kg;   Biological: Belimumab 10 mg/kg
17 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
18 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
19 Completed Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: belimumab;   Biological: Placebo
20 Completed
Has Results
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Condition: Healthy
Interventions: Biological: Single Dose Group: Belimumab IV 240 mg;   Biological: Single Dose Group: Belimumab SC 2 x 120 mg;   Biological: Single Dose Group: Belimumab SC 1 x 240 mg;   Biological: Single Dose Group: Belimumab SC 1 x 200 mg;   Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly;   Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years